Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.

BACKGROUND: Neuroendocrine tumours (NETs) are a group of heterogeneous cancers that develop in cells in the diffuse neuroendocrine system. OBJECTIVES: To estimate the clinical effectiveness of three interventions [everolimus (Afinitor®; Novartis International AG, Basel, Switzerland), lutetium-177 DO...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Health Technol Assess
Autori principali: Mujica-Mota, Ruben, Varley-Campbell, Jo, Tikhonova, Irina, Cooper, Chris, Griffin, Ed, Haasova, Marcela, Peters, Jaime, Lucherini, Stefano, Talens-Bou, Juan, Long, Linda, Sherriff, David, Napier, Mark, Ramage, John, Hoyle, Martin
Natura: Artigo
Lingua:Inglês
Pubblicazione: NIHR Journals Library 2018
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6151360/
https://ncbi.nlm.nih.gov/pubmed/30209002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3310/hta22490
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi